-+ 0.00%
-+ 0.00%
-+ 0.00%

Belite Bio Wins Nasdaq Global Select Listing, Trading Starts Oct. 19

Benzinga·10/19/2026 10:02:15
Listen to the news

Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has received approval from Nasdaq to transfer the listing of its securities from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market will commence at the open of market on October 19, 2026, under the Company’s existing ticker symbol "BLTE."